ReadGFWalkerRFFordPRiad-Fahmy. External quality assessment in small schemes: The case of 17-hydroxyprogesterone. Ann Clin Biochem1990; 27: 276–8.
2.
WallaceAMBeesleyJThomsonMGilesCARossAMTaylorNF. Adrenal status during the first month of life in mature and premature infants. J Endocrinol1987; 112: 473–80.
3.
PangSWallaceAMHofmanLDorcheCLyonICTFujeedaKSuwaS. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics1988; 81, 866–74.
4.
WallaceAMBeastallGHCookBCurrieAJRossAMKennedyRGirdwoodRWA. Neonatal screening for congenital adrenal hyperplasia: A programme based on a novel direct radioimmunoassay for 17-hydroxyprogesterone in blood spots. J Endocrinol1986; 108, 299–308.
5.
WongTEllisG. Partial characterization of substances in neonatal plasma that interfere with 17-hydroxyprogesterone assays (revised abstract). Clin Chem1990; 36: 1990.
6.
MakelaSKEllisG. Nonspecificity of a direct 17-hydroxyprogesterone radioimmunoassay kit when used with samples from neonates. Clin Chem1988; 34: 2070–5.